NeuroBo Pharmaceuticals Files 8-K
Ticker: MTVA · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, corporate-filing
TL;DR
NeuroBo Pharma filed an 8-K on Nov 4th, check it for financials & exhibits.
AI Summary
NeuroBo Pharmaceuticals, Inc. filed an 8-K on November 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly Gemphire Therapeutics Inc., is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and exhibits, which are important for investors to stay updated on the company's status.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for corporate disclosures and does not appear to contain any immediately alarming information.
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- Gemphire Therapeutics Inc. (company) — Former company name
- November 4, 2024 (date) — Date of earliest event reported
- Cambridge, Massachusetts (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 4, 2024.
What was NeuroBo Pharmaceuticals, Inc. formerly known as?
NeuroBo Pharmaceuticals, Inc. was formerly known as Gemphire Therapeutics Inc.
Where are NeuroBo Pharmaceuticals, Inc.'s principal executive offices located?
NeuroBo Pharmaceuticals, Inc.'s principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 696 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2024-11-04 08:30:23
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20241104x8k.htm (8-K) — 46KB
- nrbo-20241104xex99d1.htm (EX-99.1) — 17KB
- nrbo-20241104x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20241104xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-014184.txt ( ) — 237KB
- nrbo-20241104.xsd (EX-101.SCH) — 3KB
- nrbo-20241104_lab.xml (EX-101.LAB) — 16KB
- nrbo-20241104_pre.xml (EX-101.PRE) — 10KB
- nrbo-20241104x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 4, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") issued a press release announcing the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Report") and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solel
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated November 4, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: November 4, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer